News
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback